Polymorphism  ||| S:0 E:13 ||| NNP
of  ||| S:13 E:16 ||| IN
metalloproteinases  ||| S:16 E:35 ||| JJ
MMP-1  ||| S:35 E:41 ||| NN
and  ||| S:41 E:45 ||| CC
MMP-2  ||| S:45 E:51 ||| CD
in  ||| S:51 E:54 ||| IN
risk  ||| S:54 E:59 ||| NN
of  ||| S:59 E:62 ||| IN
laryngeal  ||| S:62 E:72 ||| JJ
cancer  ||| S:72 E:79 ||| NN
The  ||| S:79 E:83 ||| DT
laryngeal  ||| S:83 E:93 ||| JJ
cancer  ||| S:93 E:100 ||| NN
is  ||| S:100 E:103 ||| VBZ
the  ||| S:103 E:107 ||| DT
most  ||| S:107 E:112 ||| RBS
common  ||| S:112 E:119 ||| JJ
malignancy  ||| S:119 E:130 ||| NN
of  ||| S:130 E:133 ||| IN
the  ||| S:133 E:137 ||| DT
head  ||| S:137 E:142 ||| NN
and  ||| S:142 E:146 ||| CC
neck  ||| S:146 E:151 ||| NN
squamous  ||| S:151 E:160 ||| NN
cell  ||| S:160 E:165 ||| NN
carcinoma ||| S:165 E:174 ||| NN
.  ||| S:174 E:176 ||| .
Recent  ||| S:176 E:183 ||| JJ
studies  ||| S:183 E:191 ||| NNS
have  ||| S:191 E:196 ||| VBP
revealed  ||| S:196 E:205 ||| VBN
the  ||| S:205 E:209 ||| DT
role  ||| S:209 E:214 ||| NN
of  ||| S:214 E:217 ||| IN
genetic  ||| S:217 E:225 ||| JJ
variations  ||| S:225 E:236 ||| NNS
in  ||| S:236 E:239 ||| IN
the  ||| S:239 E:243 ||| DT
risk  ||| S:243 E:248 ||| NN
for  ||| S:248 E:252 ||| IN
laryngeal  ||| S:252 E:262 ||| JJ
cancer ||| S:262 E:268 ||| NN
.  ||| S:268 E:270 ||| .
Polymorphic  ||| S:270 E:282 ||| JJ
genes  ||| S:282 E:288 ||| NNS
of  ||| S:288 E:291 ||| IN
matrix  ||| S:291 E:298 ||| JJ
metalloproteinases  ||| S:298 E:317 ||| NN
may  ||| S:317 E:321 ||| MD
affect  ||| S:321 E:328 ||| VB
an  ||| S:328 E:331 ||| DT
individual  ||| S:331 E:342 ||| JJ
genetic  ||| S:342 E:350 ||| JJ
predisposition  ||| S:350 E:365 ||| NN
to  ||| S:365 E:368 ||| TO
the  ||| S:368 E:372 ||| DT
occurrence  ||| S:372 E:383 ||| NN
and  ||| S:383 E:387 ||| CC
clinical  ||| S:387 E:396 ||| JJ
implications  ||| S:396 E:409 ||| NNS
of  ||| S:409 E:412 ||| IN
the  ||| S:412 E:416 ||| DT
disease ||| S:416 E:423 ||| NN
.  ||| S:423 E:425 ||| .
THE  ||| S:425 E:429 ||| DT
AIM  ||| S:429 E:433 ||| NNP
OF  ||| S:433 E:436 ||| IN
THE  ||| S:436 E:440 ||| DT
PRESENT  ||| S:440 E:448 ||| NNP
STUDY ||| S:448 E:453 ||| NNP
:  ||| S:453 E:455 ||| :
was  ||| S:455 E:459 ||| VBD
to  ||| S:459 E:462 ||| TO
evaluate  ||| S:462 E:471 ||| VB
the  ||| S:471 E:475 ||| DT
role  ||| S:475 E:480 ||| NN
of  ||| S:480 E:483 ||| IN
polymorphic  ||| S:483 E:495 ||| JJ
variants  ||| S:495 E:504 ||| NN
of  ||| S:504 E:507 ||| IN
MMP-1  ||| S:507 E:513 ||| NNP
and  ||| S:513 E:517 ||| CC
MMP-2  ||| S:517 E:523 ||| CD
genes  ||| S:523 E:529 ||| NNS
in  ||| S:529 E:532 ||| IN
the  ||| S:532 E:536 ||| DT
development  ||| S:536 E:548 ||| NN
of  ||| S:548 E:551 ||| IN
laryngeal  ||| S:551 E:561 ||| JJ
carcinoma ||| S:561 E:570 ||| NN
.  ||| S:570 E:572 ||| .
DNA  ||| S:572 E:576 ||| NNP
was  ||| S:576 E:580 ||| VBD
extracted  ||| S:580 E:590 ||| VBN
from  ||| S:590 E:595 ||| IN
633  ||| S:595 E:599 ||| CD
individuals  ||| S:599 E:611 ||| NNS
including  ||| S:611 E:621 ||| VBG
261  ||| S:621 E:625 ||| CD
patients  ||| S:625 E:634 ||| NNS
with  ||| S:634 E:639 ||| IN
laryngeal  ||| S:639 E:649 ||| JJ
carcinoma  ||| S:649 E:659 ||| NN
and  ||| S:659 E:663 ||| CC
372  ||| S:663 E:667 ||| CD
healthy  ||| S:667 E:675 ||| JJ
volunteers ||| S:675 E:685 ||| NNS
.  ||| S:685 E:687 ||| .
Genotyping  ||| S:687 E:698 ||| NNP
was  ||| S:698 E:702 ||| VBD
carried  ||| S:702 E:710 ||| VBN
out  ||| S:710 E:714 ||| RP
using  ||| S:714 E:720 ||| VBG
TaqMan ||| S:720 E:726 ||| JJ
( ||| S:726 E:727 ||| -LRB-
® ||| S:727 E:728 ||| NNP
)  ||| S:728 E:730 ||| -RRB-
SNP  ||| S:730 E:734 ||| NNP
Genotyping  ||| S:734 E:745 ||| NNP
Assays  ||| S:745 E:752 ||| NNP
( ||| S:752 E:753 ||| -LRB-
Applied  ||| S:753 E:761 ||| NNP
Biosystems ||| S:761 E:771 ||| NNP
,  ||| S:771 E:773 ||| ,
USA ||| S:773 E:776 ||| NNP
) ||| S:776 E:777 ||| -RRB-
.  ||| S:777 E:779 ||| .
The  ||| S:779 E:783 ||| DT
distribution  ||| S:783 E:796 ||| NN
of  ||| S:796 E:799 ||| IN
polymorphisms  ||| S:799 E:813 ||| NN
of  ||| S:813 E:816 ||| IN
metalloproteinases  ||| S:816 E:835 ||| NN
were  ||| S:835 E:840 ||| VBD
analysed ||| S:840 E:848 ||| VBN
:  ||| S:848 E:850 ||| :
-1607  ||| S:850 E:856 ||| CD
1G ||| S:856 E:858 ||| CD
/ ||| S:858 E:859 ||| CD
2G  ||| S:859 E:862 ||| CD
MMP-1  ||| S:862 E:868 ||| CD
and  ||| S:868 E:872 ||| CC
-1306  ||| S:872 E:878 ||| NNP
C ||| S:878 E:879 ||| NNP
/ ||| S:879 E:880 ||| NNP
T  ||| S:880 E:882 ||| NNP
MMP-2  ||| S:882 E:888 ||| NNP
gene ||| S:888 E:892 ||| NN
.  ||| S:892 E:894 ||| .
The  ||| S:894 E:898 ||| DT
distribution  ||| S:898 E:911 ||| NN
of  ||| S:911 E:914 ||| IN
genotypes  ||| S:914 E:924 ||| NN
of  ||| S:924 E:927 ||| IN
-1607  ||| S:927 E:933 ||| CD
1G ||| S:933 E:935 ||| CD
/ ||| S:935 E:936 ||| CD
2G  ||| S:936 E:939 ||| CD
MMP-1  ||| S:939 E:945 ||| CD
polymorphism  ||| S:945 E:958 ||| NNS
was  ||| S:958 E:962 ||| VBD
significantly  ||| S:962 E:976 ||| RB
different  ||| S:976 E:986 ||| JJ
in  ||| S:986 E:989 ||| IN
controls  ||| S:989 E:998 ||| NNS
vs  ||| S:998 E:1001 ||| JJ
patients  ||| S:1001 E:1010 ||| NNS
( ||| S:1010 E:1011 ||| -LRB-
χ ||| S:1011 E:1012 ||| FW
( ||| S:1012 E:1013 ||| -LRB-
2 ||| S:1013 E:1014 ||| LS
)  ||| S:1014 E:1016 ||| -RRB-
15.05 ||| S:1016 E:1021 ||| NNP
,  ||| S:1021 E:1023 ||| ,
p  ||| S:1023 E:1024 ||| CD
< ||| S:1024 E:1025 ||| SYM
0.001 ||| S:1025 E:1030 ||| CD
) ||| S:1030 E:1031 ||| -RRB-
.  ||| S:1031 E:1033 ||| .
The  ||| S:1033 E:1037 ||| DT
2G  ||| S:1037 E:1040 ||| CD
allele  ||| S:1040 E:1047 ||| CD
carriers  ||| S:1047 E:1056 ||| NNS
of  ||| S:1056 E:1059 ||| IN
MMP-1  ||| S:1059 E:1065 ||| CD
-1607  ||| S:1065 E:1071 ||| CD
1G ||| S:1071 E:1073 ||| CD
/ ||| S:1073 E:1074 ||| CD
2G  ||| S:1074 E:1077 ||| CD
polymorphism  ||| S:1077 E:1090 ||| NNS
were  ||| S:1090 E:1095 ||| VBD
at  ||| S:1095 E:1098 ||| IN
higher  ||| S:1098 E:1105 ||| JJR
risk  ||| S:1105 E:1110 ||| NN
for  ||| S:1110 E:1114 ||| IN
laryngeal  ||| S:1114 E:1124 ||| JJ
carcinoma  ||| S:1124 E:1134 ||| JJ
development  ||| S:1134 E:1146 ||| NN
( ||| S:1146 E:1147 ||| -LRB-
p  ||| S:1147 E:1148 ||| FW
< ||| S:1148 E:1149 ||| SYM
0.001 ||| S:1149 E:1154 ||| FW
) ||| S:1154 E:1155 ||| -RRB-
.  ||| S:1155 E:1157 ||| .
In  ||| S:1157 E:1160 ||| IN
the  ||| S:1160 E:1164 ||| DT
present  ||| S:1164 E:1172 ||| JJ
study ||| S:1172 E:1177 ||| NN
,  ||| S:1177 E:1179 ||| ,
2G ||| S:1179 E:1181 ||| CD
/ ||| S:1181 E:1182 ||| CD
2G  ||| S:1182 E:1185 ||| CD
polymorphic  ||| S:1185 E:1197 ||| CD
variant  ||| S:1197 E:1205 ||| NNS
was  ||| S:1205 E:1209 ||| VBD
the  ||| S:1209 E:1213 ||| DT
independent  ||| S:1213 E:1225 ||| JJ
factor  ||| S:1225 E:1232 ||| NN
of  ||| S:1232 E:1235 ||| IN
cancer  ||| S:1235 E:1242 ||| NN
development  ||| S:1242 E:1254 ||| NN
( ||| S:1254 E:1255 ||| -LRB-
p=0.0015 ||| S:1255 E:1263 ||| NNP
) ||| S:1263 E:1264 ||| -RRB-
.  ||| S:1264 E:1266 ||| .
Presented  ||| S:1266 E:1276 ||| VBN
data  ||| S:1276 E:1281 ||| NNS
suggest  ||| S:1281 E:1289 ||| VBP
an  ||| S:1289 E:1292 ||| DT
implication  ||| S:1292 E:1304 ||| NN
of  ||| S:1304 E:1307 ||| IN
MMP-1  ||| S:1307 E:1313 ||| CD
polymorphisms  ||| S:1313 E:1327 ||| NN
in  ||| S:1327 E:1330 ||| IN
the  ||| S:1330 E:1334 ||| DT
laryngeal  ||| S:1334 E:1344 ||| JJ
carcinoma  ||| S:1344 E:1354 ||| JJ
susceptibility ||| S:1354 E:1368 ||| NN
.  ||| S:1368 E:1370 ||| .
The  ||| S:1370 E:1374 ||| DT
presence  ||| S:1374 E:1383 ||| NN
of  ||| S:1383 E:1386 ||| IN
the  ||| S:1386 E:1390 ||| DT
MMP-1  ||| S:1390 E:1396 ||| CD
2G  ||| S:1396 E:1399 ||| CD
allele  ||| S:1399 E:1406 ||| NNS
seemed  ||| S:1406 E:1413 ||| VBD
to  ||| S:1413 E:1416 ||| TO
be  ||| S:1416 E:1419 ||| VB
associated  ||| S:1419 E:1430 ||| VBN
with  ||| S:1430 E:1435 ||| IN
increased  ||| S:1435 E:1445 ||| JJ
risk  ||| S:1445 E:1450 ||| NN
for  ||| S:1450 E:1454 ||| IN
the  ||| S:1454 E:1458 ||| DT
disease ||| S:1458 E:1465 ||| NN
.  ||| S:1465 E:1467 ||| .
In  ||| S:1467 E:1470 ||| IN
summary ||| S:1470 E:1477 ||| NN
,  ||| S:1477 E:1479 ||| ,
the  ||| S:1479 E:1483 ||| DT
current  ||| S:1483 E:1491 ||| JJ
study  ||| S:1491 E:1497 ||| NN
have  ||| S:1497 E:1502 ||| VBP
provided  ||| S:1502 E:1511 ||| VBN
the  ||| S:1511 E:1515 ||| DT
evidence  ||| S:1515 E:1524 ||| NN
that  ||| S:1524 E:1529 ||| IN
an  ||| S:1529 E:1532 ||| DT
individual ||| S:1532 E:1542 ||| NN
's  ||| S:1542 E:1545 ||| POS
risk  ||| S:1545 E:1550 ||| NN
for  ||| S:1550 E:1554 ||| IN
carcinoma  ||| S:1554 E:1564 ||| NN
of  ||| S:1564 E:1567 ||| IN
larynx  ||| S:1567 E:1574 ||| NN
is  ||| S:1574 E:1577 ||| VBZ
modulated  ||| S:1577 E:1587 ||| VBN
by  ||| S:1587 E:1590 ||| IN
genetic  ||| S:1590 E:1598 ||| JJ
factors ||| S:1598 E:1605 ||| NNS
.  ||| S:1605 E:1607 ||| .
